L'homme Rafaëlla Fa, Nijland Hanneke M J, Gras Luuk, Aarnoutse Rob E, van Crevel Reinout, Boeree Martin, Brinkman Kees, Prins Jan M, Juttmann Job R, Burger David M
Department of Clinical Pharmacy, Radboud University Nijmegen Medical Centre, 6525 GA Nijmegen, The Netherlands.
AIDS. 2009 Apr 27;23(7):863-5. doi: 10.1097/QAD.0b013e328329148e.
Thirty-four patients treated concomitantly with lopinavir/ritonavir and rifampicin were evaluated. Overall, only 15% used the recommended increased dose of lopinavir/ritonavir. Of patients on a nonadjusted dose of lopinavir/ritonavir, 67% had a subtherapeutic lopinavir plasma concentration and 38% had a detectable viral load. Forty percent of patients on an increased dose of lopinavir/ritonavir prematurely stopped the drug combination because of adverse events. Combined use of lopinavir/ritonavir and rifampicin is challenging as it implies balancing between suboptimal efficacy and toxicity.
对34例同时接受洛匹那韦/利托那韦和利福平治疗的患者进行了评估。总体而言，只有15%的患者使用了推荐增加剂量的洛匹那韦/利托那韦。在未调整洛匹那韦/利托那韦剂量的患者中，67%的患者洛匹那韦血浆浓度低于治疗水平，38%的患者病毒载量可检测到。40%接受增加剂量洛匹那韦/利托那韦治疗的患者因不良事件而提前停止了药物联合治疗。洛匹那韦/利托那韦与利福平的联合使用具有挑战性，因为这意味着要在疗效欠佳和毒性之间取得平衡。
